Literature DB >> 15523692

Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13.

Jong Myun Park1, Masaki Terabe, Leon T van den Broeke, Debra D Donaldson, Jay A Berzofsky.   

Abstract

We have previously observed a novel role of natural killer T (NKT) cells in negative regulation of antitumor immune responses against an immunogenic regressor tumor expressing a transfected viral antigen. Here, we investigated whether hidden spontaneous antitumor immunosurveillance, in the absence of a vaccine, could be revealed by disruption of this negative regulatory pathway involving CD4+ NKT cells and interleukin-13 (IL-13), in a murine pulmonary metastasis model of a nontransfected, nonregressor, syngeneic tumor, the CT26 colon carcinoma. Lung metastases of CT26 were decreased in CD4+ T cell-depleted BALB/c mice, suggesting that CD4+ T cells were involved in negative regulation of antitumor responses. CD1-knock out (CD1-KO) mice, which have conventional CD4+ T cells and CD4+CD25+ regulatory T cells but lack CD1-restricted CD4+ NKT cells, were significantly resistant to lung metastasis of CT26. The metastases were not further decreased in CD4+ T cell-depleted CD1-KO mice, implying that CD4+ NKT cells might be the primary negative regulator of antitumor immune responses in BALB/c mice. CD8+ T cells were found to act as effectors in antitumor immune responses, since the inhibition of lung metastases observed in naive CD1-KO or CD4+ T cell-depleted mice was abrogated by depletion of CD8+ T cells. Lung metastases were significantly decreased by treatment of mice with an IL-13 inhibitor, but not by deficiency or inhibition of IL-4. Thus, even for a nonregressor tumor, immunosurveillance exists but is negatively regulated via CD4+ NKT cells possibly mediated by IL-13, and can be unmasked by removal of these negative regulatory components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15523692     DOI: 10.1002/ijc.20669

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  33 in total

Review 1.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

2.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

Review 3.  Intestinal inflammation and colorectal cancer: a double-edged sword?

Authors:  Angelamaria Rizzo; Francesco Pallone; Giovanni Monteleone; Massimo Claudio Fantini
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

4.  Type I natural killer T cells suppress tumors caused by p53 loss in mice.

Authors:  Jeremy B Swann; Adam P Uldrich; Serani van Dommelen; Janelle Sharkey; William K Murray; Dale I Godfrey; Mark J Smyth
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

5.  Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.

Authors:  Jie Zhao; Xiufang Weng; Sreya Bagchi; Chyung-Ru Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

6.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

7.  Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin.

Authors:  Jessica J O'Konek; Elena Ambrosino; Anja C Bloom; Lise Pasquet; Chandirasegaran Massilamany; Zheng Xia; Masaki Terabe; Jay A Berzofsky
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

8.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Authors:  Shun Takaku; Masaki Terabe; Elena Ambrosino; Judy Peng; Scott Lonning; John M McPherson; Jay A Berzofsky
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

Review 9.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

10.  A comprehensive ex vivo functional analysis of human NKT cells reveals production of MIP1-α and MIP1-β, a lack of IL-17, and a Th1-bias in males.

Authors:  Jennifer E Snyder-Cappione; Camilla Tincati; Ijeoma G Eccles-James; Amedeo J Cappione; Lishomwa C Ndhlovu; Laura L Koth; Douglas F Nixon
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.